Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116586 | 1.00 | PTGDR2 (0.73) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4116584 | 1.00 | PTGDR2 (0.73) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4122778 | 0.92 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4133326 | 0.92 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4122781 | 0.92 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL16187786 | 0.85 | PTGDR2 (0.61) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4115229 | 0.85 | PTGDR2 (0.61) | PTGDR2MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4119071 | 0.85 | PTGDR2 (1.00) | PTGDR2MEN1KMT2A | |
| SCHEMBL5394167 | 0.85 | PTGDR2 (1.00) | PTGDR2MEN1KMT2A | |
| SCHEMBL4119068 | 0.85 | PTGDR2 (1.00) | PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070197587-A1 | Quinoline Derivatives as CRTH2 Antagonists | PFIZER INC | 2007-08-23 | — | — | US | disclosed |
| US-7220760-B2 | Quinoline derivatives as CRTH2 antagonists | PFIZER INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1556356-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER LAMBERT CO (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1556356-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132772-A1 | 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis | WARNER-LAMBERT COMPANY LLC | 2004-07-08 | — | — | US | disclosed |
| EP-1435356-A1 | Quinoline derivatives as CRTH2 antagonists | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004035543-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1413306-A1 | Tetrahydroquinoline derivatives as CRTH2 antagonists | Warner-Lambert Company LLC (US) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132772-A1 | 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis | HRH1, HRH2, HRH4 | PTGDR2 748/4885MEN1 2397/4885KMT2A 906/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | PTGDR2 1/4885MEN1 4611/4885KMT2A 4216/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | PTGDR2 1/4885MEN1 4611/4885KMT2A 4216/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | PTGDR2 1/4885MEN1 4739/4885KMT2A 4627/4885 |
| US-20070197587-A1 | Quinoline Derivatives as CRTH2 Antagonists | HRH2, HRH1, HRH3 | PTGDR2 120/4885MEN1 2435/4885KMT2A 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.